Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Placebo-controlled, Open-label, Phase 2b Clinical Trial to Evaluate the Antitumor Activity of Combination Therapy of SMT-NK and Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer

NCT05429697 is registered in ClinicalTrials.gov with SMT bio Co., Ltd. as lead sponsor.

NCT NCT05429697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05429697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Placebo-controlled, Open-label, Phase 2b Clinical Trial to Evaluate the Antitumor Activity of Combination Therapy of SMT-NK and Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer
Lead sponsor
SMT bio Co., Ltd.
Phase
Phase 2/3
Overall status
Unknown status
Start date
June 9, 2022
Completion date
June 8, 2026
Enrollment
128 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer